Eli Lilly and CompanyLLYNYSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+47.8%
5Y CAGR+25.7%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+47.8%/yr
vs +11.9%/yr prior
5Y CAGR
+25.7%/yr
Recent acceleration
Acceleration
+35.9pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $27.94B | +83.5% |
| 2024 | $15.23B | +77.7% |
| 2023 | $8.57B | -1.1% |
| 2022 | $8.66B | +7.7% |
| 2021 | $8.04B | -9.8% |
| 2020 | $8.91B | +29.2% |
| 2019 | $6.90B | +24.7% |
| 2018 | $5.53B | +35.0% |
| 2017 | $4.10B | -19.0% |
| 2016 | $5.06B | - |